01 Jul 2022 - 01 Aug 2022


CS-IRG New Investigator Grant (CS-IRG-NIG) is a sub category of the CS-IRG to cater for new clinical investigators. The CS-IRG-NIG is a step for the new investigator towards winning a first independent national level grant. Applicants with substantial research experience will not be accepted under this category.

Research Themes:

The CS-IRG-NIG is open to application on all research themes. Applications are assessed based on scientific merit and relevance to Singapore, but should prioritisation be required between meritorious applications, the following seven disease areas have been identified as national priorities for research:

  • Cancers and neoplasms
  • Cardiovascular
  • Eye
  • Infection
  • Mental health
  • Metabolic and endocrine
  • Neurological

Evaluation Criteria:

Selection of successful proposals would be based on the following evaluation criteria:

  • Scientific excellence
  • Feasibility of study in local context
  • Productivity
  • Overall impact in local context
  • Suitability of applicant to be an independent investigator and to assume the role of a PI

To be eligible for the CS-IRG-NIG, the following requirements apply:

(i) Awardees of the following grants as PI/Co-PI* at the point of application will not be eligible for the NIG: A*STAR Investigatorship, NRF Fellowship, NMRC CSA and STaR, MOE Tier 2 and 3 grants, MOH/NMRC IRG-equivalent grants^.

*Co-PIs refer to PIs whose projects are jointly led by other PIs (e.g. projects under NMRC’s Bedside & Bench grant). They are not the same as, and should not be confused with Co-Investigators (Co-Is).
^NIC Ageing Grants (with the exception of Health and Longevity Catalyst Awards) are considered IRG-equivalent grants.

(ii) Applicants must not have received external competitive funding exceeding $500,000 (direct costs only), to conduct their own research project as the PI. 

Applicants who are applying under the new investigator category (CS-IRG-NIG) have to work with a mentor for guidance in their research. This mentoring will provide support for a period of supervised research leading eventually to the clinical investigators conducting larger scale research projects independently. Please note that the NIG is intended to fund a new investigator’s independent project, and not to provide additional funding for the mentor's project (or clinical trial). 


Each CS-IRG-NIG application must be led by a Clinical Principal Investigator (PI) who has to fulfill the eligibility criteria listed below:

  1. PI must be clinically qualified (i.e. with MD/MBBS/BDS) and preferably with post-graduate clinical training and experience.
  2. Allied Health Professionals who meet the following conditions may apply:
    1. Non-medically trained PIs who are nurses, pharmacists or other allied health professions listed on the MOH’s website in clinical practice, doing research in clinical settings or doing research with clinical and healthcare applications/relevance, are eligible to apply.
    2. Applicants who are working in human clinical research, including epidemiologists, biostatisticians, and whose research is clinically relevant and has potential health impact, will be considered as exceptions on a case-by-case basis.
    3. Non-medically trained applicants conducting wet laboratory based research are not eligible.
    4. Applicants must possess a minimum academic qualification of a PhD or the equivalent training.
    5. Recipients of NMRC Human Capital Awards, Transition Award and NMRC Research Training Fellowship are eligible to apply.
  3. A*STAR CS scholar from the National Science Scholarship (NSS) (MBBS-PhD) or NSS (MD-PhD) schemes and who fulfil the following may apply:
    1. hold primary appointments in Academic Medical Centres (AMCs), public health institutions (PHIs) or medical schools; or
    2. hold primary appointments in A*STAR but (with mutual agreement of A*STAR and the AMC/PHI/medical school) also hold a joint appointment in the AMC/PHI/medical school, provided that any such grant application is supported by the AMC/PHI/medical school.The institution/school should also consider if these A*STAR CS scholars are able to demonstrate that they can act as a bridge between A*STAR and the healthcare system.
    3. submit the grant application through AMCs/PHIs/medical schools as host institutions.
  4. For proposals involving patients, the clinical PI or co-I should be SMC registered; or should be able to demonstrate ability to access patients through SMC registered collaborators. For some CS-IRG-NIG proposals it is recognized that some studies may be pre-clinical and not require the PI to be SMC registered.
  5. Only one PI is allowed per application. The number of applications by an individual (as PI) is capped at 1 grant application per grant type in a grant call.

Additional eligibility criteria include:

(a)  Hold a primary appointment in a local public hospital/public health institutions/national specialty centre/public universities/Academic Medical Centres and salaried by the institution.

(b)  Have access to a laboratory or clinical research program that carries out research in Singapore.

(c)  Hold a minimum of 9 months employment with a local public institution. Upon award, the PI must agree to fulfill at least 6 months of residency in Singapore for each calendar year over the duration of the grant award. 

(d) No outstanding reports from previous BMRC, NMRC grants and other national grants.

Funding Quantum:

The CS-IRG-NIG will provide a funding quantum of up to S$260,000 (inclusive of up to 30% indirect costs^) for 2 years with up to additional 30% indirect costs provided to the host institution of the PI. Projects involving prospective patient/subject recruitment may apply for a funding duration of up to 3 years, subject to the same funding quantum.

Grant Call Frequency:

There will be two grant calls per year (Jan and Jul). 


It is mandatory for all applications to be submitted and endorsed by the Host Institution's Director of Research (DOR) online via IGMS by 1 August 2022, 5pm. We will not entertain any late submissions or submissions from individual applicants without endorsement from the Host Institution.

Please download the CS-IRG-NIG Guide and Application Form for more information. 

Review Panel:

The composition of the CS-IRG Review Panel (2021-2022) is listed in the table below.





Prof Yap Seng CHONG (Co-Chair)

Dean, Yong Loo Lin School of Medicine, National University of Singapore

Lien Ying Chow Professor, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore

Executive Director, Singapore Institute for Clinical Sciences, A*STAR

Founding Director, A*STAR-NUS Singapore Centre for Nutritional Science, Metabolic Disease and Human Development


Prof Thomas COFFMAN (Co-Chair)

Dean, Duke-NUS Medical School

Professor, Cardiovascular & Metabolic Disorders Programme, Duke-NUS

James R. Clapp Professor, Medicine, Duke University Medical Center


A/Prof Allen YEOH

Associate Professor, Department of Paediatrics

Senior Consultant, Division of Paediatric Haematology and Oncology, Khoo Teck Puat-National University Children’s Medical Institute, National University Hospital



Professor, Cardiovascular Epidemiology, Lee Kong Chian School of Medicine, Nanyang Technological University

President’s Chair in Cardiovascular Epidemiology


Prof Eng Eong OOI

Professor, Programme in Emerging Infectious Diseases, Duke-NUS Medical School

Professor, Department of Microbiology & Immunology, National University of Singapore

Professor, Saw Swee Hock School of Public Health, National University of Singapore

Co-Director, Viral Research and Experimental Medicine Centre @ SingHealth Duke-NUS (ViREMiCS)


Prof Kah Leong LIM

Vice-Dean of Research and Professor, Lee Kong Chian School of Medicine, Nanyang Technological University

President’s Chair, Translational Neuroscience, Lee Kong Chian School of Medicine, Nanyang Technological University


A/Prof Su Chi LIM

Clinical Director, Clinical Research Unit, Khoo Teck Puat Hospital


Prof Woon Puay KOH

Assistant Dean for Faculty Development, Yong Loo Lin School of Medicine, National University of Singapore

Principal Investigator, Healthy Longevity Translational Research Programme, National University of Singapore

 9 Prof Pierce CHOW Senior Consultant, Hepato-pancreato-biliary and Transplant Surgery, Singapore General Hospital

Senior Consultant, Division of Surgical Oncology, National Cancer Centre Singapore

Professor and Program Director, PhD Programme in Clinical Sciences, Duke-NUS Medical School

Academic Vice Chair (Research), Academic Clinical Programme for Surgery (SURG ACP)
 10 Prof David VIRSHUP Honorary Joint Professor, Department of Biochemistry, Yong Loo Lin School of Medicine, NUS

Program Director for Cancer & Stem Cell Biology, Duke-NUS Graduate Medical School
 11 Prof Mark RICHARDS Director Cardiovascular Research Institute (CVRI)

Deputy Director National University Heart Centre Singapore (NUHCS) 
 12 A/Prof Vijay K SHARMA Associate Professor, Yong Loo Lin School of Medicine, National University of Singapore

Senior Consultant, Division of Neurology, Department of Medicine, National University Hospital


Prof Joseph Wan Yee LAU

Research Professor, Faculty of Medicine, The Chinese University of Hong Kong, HK


Prof Bernard MY CHEUNG

Sun Chieh Yeh Heart Foundation Professor in Cardiovascular Therapeutics

Chief, Division of Clinical Pharmacology & Therapeutics, Department of Medicine, University of Hong Kong, HK


Prof Calvin Chi Pui PANG

S.H. Ho Research Professor of Visual Sciences, Chinese University of Hong Kong, HK

Director, Shantou University/Chinese University of Hong Kong Joint Shantou International Eye Center, HK


Prof Xin CHEN

Distinguished professor of biomedical sciences and Interim Director, Institute of Chinese Medical Sciences

Distinguished professor of Biomedical Sciences, Department of Pharmaceutical Sciences, Faculty of Health Sciences,

University of Macau


Prof Patrick G. KEHOE

Professor, Translational Dementia Research/Medical School Research Director, University of Bristol, UK


Prof Dale L. BARNARD

Emeritus Professor, Institute of Antiviral Research, USA


Prof Kyong Soo PARK

Director, Center for Precision Medicine, Seoul National University, KR

 20 Prof Ian CAMPBELL Co-Head, Women’s Cancer Program, Peter MacCallum Cancer Centre

Head, Cancer Genetics Laboratory, Sir Peter MacCallum Department of Oncology at the University of Melbourne, Australia

Principal Investigator, Lifepool
 21 Prof Anskar LEUNG Professor, Chair of Haematology

Li Shu Fan Medical Foundation Professor in Haematology
Department of Medicine
School of Clinical Medicine
LKS Faculty of Medicine
University of Hong Kong

 22 Prof Mark COOPER Head of Department of Diabetes, Central Clinical School, Monash University

Applicants are not allowed to approach any of the panel members to discuss or solicit information related to their application review or funding decisions. NMRC may impose a suspension and/or debarment on such applicants.